Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-06-22

Reporting Person: KINGSLEY ALFRED D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-22	Common Shares, no par value	M	61800	$2.20	Acquired	5470245	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-22	Stock Option (right to buy)	$2.20	M	61800	Disposed	2021-06-30	Common Shares (61800)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, no par value	1043346	Indirect
Common Shares, no par value	375351	Indirect

Footnotes

F1: Held by Greenbelt Corporation, of which Mr. Kingsley is an executive officer, director, and controlling shareholder. Mr. Kingsley disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest.

F2: Held by Greenway Partners, LP, of which Mr. Kingsley is the General Partner and has sole voting and dispositive control.

F3: This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.